SignatureFD’s Benitec Biopharma BNTC Stock Holding History

SignatureFD’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-170	Closed	-$1.81K	–	3525
2026 Q1	$1.81K	Buy	+170	New	+$1.97K	﹤0.01%	3084

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

SignatureFD's BNTC Position: Q2 2026 in Review

SignatureFD sold out of Benitec Biopharma (BNTC) in Q2 2026, closing a stake of 170 shares — an estimated $1.81K sold.

SignatureFD first reported a position in BNTC in Q1 2026 and held it in 1 quarter. The position peaked at $1.81K in Q1 2026. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

SignatureFD reported no remaining Benitec Biopharma position as of Q2 2026 after selling out during the quarter.
SignatureFD sold 170 Benitec Biopharma shares in Q2 2026, an estimated $1.81K.
SignatureFD first reported a position in Benitec Biopharma in Q1 2026 and held it in 1 quarter.
SignatureFD's Benitec Biopharma position peaked at $1.81K in Q1 2026.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.